viewPreveCeutical Medical Inc.

PreveCeutical says C$16.25M Crushedit supply deal and Asterion Cannabis licensing deal among 2018 milestones

The company says other accomplishments include the start of a medicinal cannabis division, completion of C$6.5 million in financing and expansion of Australian operations

A greenhouse with marijuana plants
Other accomplishments include the start of a medicinal cannabis division

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) said Wednesday that a letter of intent with Crushedit LLC regarding a C$16.25 million cannabidiol isolate supply agreement and a natural-health- product licensing deal with Asterion Cannabis Inc are among the milestones achieved in 2018.

Vancouver-based PreveCeutical said in a press release that its other accomplishments include the start of a medicinal cannabis division, completion of a C$6.5 million financing and expansion of its Australian operations.

READ: PreveCeutical Medical reports converting acid phytocannabinoids to neutral form

The company added that it has reached its 2018 research targets for its scorpion venom-derived peptide program and its soluble gel drug delivery platform program. PreveCeutical also said it completed a workshop in Australia to advance its dual gene therapy research and development program.

Shares of PreveCeutical fetched C$0.05 in Wednesday’s Canadian trading and US$0.04 on the OTC Markets.

In November, the company announced that it had entered into a letter of intent with Nevada-registered Crushedit, under which PreveCeutical's cannabis division would supply Crushedit with at least 2,500 kilograms of CBD isolate over 12 months at C$6,500 per kilogram, for a total of at least C$16.25 million.

PreveCeutical added Wednesday that its letter of intent with the Penta 5 Group has expired. PreveCeutical said complexities regarding the structure of the group made a proposed share purchase transaction unfeasible. The companies are in negotiations regarding possible alternative transaction structures, according to PreveCeutical.

In August, Asterion granted PreveCeutical a worldwide license to use, manufacture, distribute and sell three Health Canada-approved natural-health products.

Last month, the company said it had developed a way to convert phytocannabinoids extracted from the company's five cannabis strains from acid to neutral.

Contact Dennis Fitzgerald at [email protected]

Quick facts: PreveCeutical Medical Inc.

Price: 0.035 CAD

Market: CSE
Market Cap: $13.88 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...



Full interview: Preveceutical announces successful preliminary evaluation of...

Preveceutical (CSE:PREV-OTCQB: PRVCF) President Mak Jawadeker joined Steve Darling from Proactive Vancouver on Skype to discuss the company successfully completing the design, synthesis and preliminary evaluation of key peptides from its scorpion venom-derived peptide research and development...

on 15/11/19

2 min read